Complete remission from chronic myelogenous leukemia--blastic crisis caused by reduced intensity stem cell transplantation following partial remission due to imatinib.
We report a 55-year-old man who showed no change after chemotherapy for chronic myelogenous leukemia-blastic crisis (CML-BC) in 1998. Allo-peripheral blood stem cell transplantation (PBSCT) was then performed and Complete remission (CR) was achieved, but recurrence was seen in 2001. Imatinib administration brought about partial remission (PR) and then a reduced intensity stem cell transplantation (RIST) was performed. The bcr-abl gene disappeared and Ph1 chromosome disappearance was ascertained. CR was thus achieved. There are still no established radical methods of treating CML-BC. Thus, therapy by allograft after the patient has entered hematological remission with imatinib is considered a new way of dealing with cases of CML-BC.
Myojo
Tomohiro
T
Department of Internal Medicine, Kure Kyosai Hospital, 2-3-28 Nishichuo, Kure 737-8505.
Hino
Norihiko
N
D001549:Benzamides; D001752:Blast Crisis / Q000188:drug therapy*; D001853:Bone Marrow / Q000473:pathology; D016313:Genes, abl; D006801:Humans; D006965:Hyperplasia; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000627:therapeutic use*; D014178:Translocation, Genetic
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases